Vaccine for children: Bharat Biotech awaits further regulatory approval

Gallery

MORE...

Sports

Men’s Sr Hockey Nationals to be played in division-based format from April 4

The 15th Hockey India Senior Men National Championship, set to take place from April 4 to

Mensik denies Djokovic 100th title in Miami final

KIPG: Son of a vegetable vendor, Bihar’s Jhandu Kumar eyes Worlds, 2028 Paralympics

Hardik Singh credits hard work and team unity for receiving HI Midfielder of the Year award

Djokovic, Alcaraz land in same half of Miami draw

India to host 2nd Asian Yogasana Championships from March 29 to 31

MORE...

Vaccine for children: Bharat Biotech awaits further regulatory approval

Last Updated : 12 Oct 2021 05:21:21 PM IST

Vaccine for children: Bharat Biotech awaits further regulatory approval

Vaccine maker Bharat Biotech on Tuesday said that it is awaiting further regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) for its Covid-19 vaccine Covaxin for the 2-18 years age group.

The Hyderabad-based company submitted data from clinical trials of the vaccine in the 2-18 years age group to CDSCO.

The data has been thoroughly reviewed by the CDSCO and Subject Experts Committee (SEC) and have given their positive recommendations, the company said.

According to the form, this represents one of the first approvals worldwide for Covid-19 vaccines for the 2-18 age group.

"Bharat Biotech sincerely thank the DCGI, Subject Experts Committee, and CDSCO for their expedited review process. We now await further regulatory approvals from the CDSCO prior to product launch and market availability of Covaxin for children," it said.